Guillaume Medard

Guillaume Médard is group leader for chemical proteomics and teaches chemical biology at the Technical University of Munich (TUM School of Life Sciences). He has a diplôme d’ingénieur from the École Nationale Supérieure de Chimie de Montpellier, and an organic chemistry research masters from the University of Strasbourg. In 2009, he was awarded a PhD by University College London for his contribution to 9,10-secosteroids semi- and total synthesis. Guillaume has worked four years in the UK as a research scientist for the CRO Argenta Discovery (now Charles River), where he contributed to kinase inhibitors drug discovery programmes for Genentech. In 2011, he was invited by Bernhard Küster to lead chemical proteomics within the TUM chair of proteomics. The Médard group’s main ambition is to help expanding the addressable proteome by coupling medicinal chemistry and bottom-up proteomics. A particular focus is put on affinity-based chemoproteomics using on-bead immobilised small molecules. The group notably develops chemoproteomics profiling technologies for kinase and HDAC inhibitors, target deconvolution protocols for man-made and nature-made molecules, as well as proteome-wide screening and SAR methods. The group is involved in many collaborations with biologists and medicinal chemists, including as a EU-Openscreen partner site for chemoproteomics.